Psychiatric adverse events during levetiracetam therapy.
The prevalence and psychopathologic features of psychiatric adverse events (PAE) in 517 patients taking levetiracetam (LEV) were investigated. Fifty-three (10.1%) patients developed PAE. A significant association was found with previous psychiatric history, history of febrile convulsions, and history of status epilepticus, whereas lamotrigine co-therapy had a protective effect. PAE were not related to the titration schedule of LEV, and certain patients seem to be biologically more vulnerable.
Mula
M
M
Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, UK.
Trimble
M R
MR
Yuen
A
A
Liu
R S N
RS
Sander
J W A S
JW
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000009:adverse effects* / Q000031:analogs & derivatives*; D015995:Prevalence; D011605:Psychoses, Substance-Induced / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology*; D012307:Risk Factors
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam